Q-omics provides the consensus-scored NMUR2 profile across patient tissues and cancer cell-line models. NMUR2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NMUR2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, NMUR2 RNA expression shows 13,480 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where NMUR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NMUR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NMUR2 survival associations across molecular data types. NMUR2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NMUR2 RNA expression–survival associations across cancer types. High NMUR2 expression shows unfavorable associations in KIRP, UVM, THYM and SKCM, but favorable associations in ESCA and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NMUR2 RNA expression.
This table summarizes NMUR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NMUR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NMUR2 shows lower tumor expression in KIRC, KICH, THCA, KIRP and LUAD and higher tumor expression in COAD. The KIRC box plot shows higher NMUR2 RNA expression in normal versus tumor tissue (log2 FC = −0.740, t-test p < 0.001).
This table shows molecular features associated with NMUR2 in patient tissues and cancer cell lines. In patient samples, NMUR2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NMUR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and PANCREAS.
